Mitochondria-targeted doxorubicin: A new therapeutic strategy against doxorubicin-resistant osteosarcoma

Molecular Cancer Therapeutics

Volumn 15, Issue 11, 2016, Pages 2640-2652

  Buondonno, Ilaria ^a   Gazzano, Elena ^a   Jean, Sae Rin ^b   Audrito, Valentina ^a,c   Kopecka, Joanna ^a   Fanelli, Marilù ^d   Salaroglio, Iris C ^a   Costamagna, Costanzo ^a   Roato, Ilaria ^e   Mungo, Eleonora ^a   Hattinger, Claudia M ^d   Deaglio, Silvia ^a,c   Kelley, Shana O ^b   Serra, Massimo ^d   Riganti, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c Human Genetics Foundation   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; MITOCHONDRIA TARGETED DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARDIOTOXICITY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OSTEOSARCOMA; PHAGOCYTOSIS; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION; ANIMAL; BONE NEOPLASMS; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENERGY METABOLISM; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BONE NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; OSTEOSARCOMA; OXIDATION-REDUCTION; P-GLYCOPROTEINS; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995446697     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0048     Document Type: Article

References (48)

1. Rivera-Valentin RK, Zhu L, Hughes DP. Bone sarcomas in pediatrics: Progress in our understanding of tumor biology and implications for therapy. Paediatr Drugs 2015; 17: 257-71.
2. Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015; 20: 495-514.
3. Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL. Anthracycline-related cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol 2014; 29: 103-12.
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
5. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5.
6. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003; 21: 536-42.
7. Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 2006; 29: 1459-68.
8. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: A systematic review. Eur J Surg Oncol 2009; 35: 1030-6.
9. Condello M, Cosentino D, Corinti S, Di Felice G, Multari G, Gallo FR, et al. Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts. J Nat Prod 2014; 77: 855-62.
10. Xia YZ, Ni K, Guo C, Zhang C, Geng YD, Wang ZD, et al. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling. Phytomedicine 2015; 22: 344-51.
11. Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, et al. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 2014; 14: E681.
12. Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, et al. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer 2014; 110: 2896-904.
13. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010; 5: E10764.
14. Roncuzzi L, Pancotti F, Baldini N. Involvement of HIF-1a activation in the doxorubicin resistance of human osteosarcoma cells. Oncol Rep 2014; 32: 389-94.
15. Sero V, Tavanti E, Vella S, Hattinger CM, Fanelli M, Michelacci F, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs 2014; 32: 1167-80.
16. Armstrong J, Dass CR. Doxorubicin action on mitochondria: Relevance to osteosarcoma therapy? Curr Drug Targets 2015 Apr 16. [Epub ahead of print].
17. Riganti C, Rolando B, Kopecka J, Campia I, Chegaev K, Lazzarato L, et al. Mitochondrial-targeting nitrooxy-doxorubicin: A new approach to overcome drug resistance. Mol Pharm 2013; 10: 161-74.
18. Chamberlain GR, Tulumello DV, Kelley SO. Targeted delivery of doxorubicin to mitochondria. ACS Chem Biol 2013; 8: 1389-95.
19. Jean SR, Tulumello DV, Riganti C, Liyanage SU, Schimmer AD, Kelley SO. Mitochondrial targeting of doxorubicin eliminates nuclear effects associated with cardiotoxicity. ACS Chem Biol 2015; 10: 2007-15.
20. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993; 13: 323-9.
21. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116: 1827-35.
22. Brunetti G, Rizzi R, Oranger A, Gigante I,Mori G, Taurino G, et al. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget 2014; 5: 12950-67.
23. Gelsomino G, Corsetto PA, Campia I, MontorfanoG, Kopecka J, Castella B, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by downregulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 2013; 12: E137.
24. Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/GSK3/b-catenin pathway. Neuro- Oncol 2013; 15: 1502-17.
25. Campia I, Lussiana C, Pescarmona G, Ghigo D, Bosia A, Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br J Pharmacol 2009; 158: 1777-86.
26. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005; 65: 516-25.
27. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 2013; 8: E60975.
28. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med 2007; 13: 54-61.
29. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 2014; 16: 992-1003.
30. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 2004; 279: 47726-31.
31. Gaster M, Rustan AC, Aas V, Beck-Nielsen H. Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin evidence from cultured myotubes. Diabetes 2004; 53: 542-8.
32. Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Lett 2015; 360: 219-26.
33. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: E955691
34. Horton KL, Stewart KM, Foseca SB, Guo Q, Kelley SO. Mitochondriapenetrating peptides. Chem Biol 2008; 15: 375-82.
35. De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, et al. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer 2009; 8: E108.
36. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: Moving towards more personalized medicine. Trends Mol Med 2008; 14: 141-51.
37. Biswas G, Guha M, Avadhani NG. Mitochondria-to-nucleus stress signaling in mammalian cells: Nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene 2005; 354: 132-9.
38. Zhang Y, Liu L, Jin L, Yi X, Dang E, Yang Y, et al. Oxidative stress-induced calreticulin expression and translocation: New insights into the destruction of melanocytes. J Invest Dermatol 2014; 134: 183-91.
39. Poston CN, Krishnan SC, Bazemore-Walker CR. In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM). J Proteomics 2013; 79: 219-30.
40. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, et al. Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle 2011; 10: 4208-16.
41. Mailloux RJ, Harper ME. Mitochondrial proticity and ROS signaling: Lessons from the uncoupling proteins. Trends Endocrinol Metab 2012; 23: 451-8.
42. Marcillat O, Zhang Y, Davies KJ. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J 1989; 259: 181-9.
43. Strigun A, Wahrheit J, Niklas J, Heinzle E, Noor F. Doxorubicin increases oxidative metabolismin HL-1 cardiomyocytes as shown by 13Cmetabolic flux analysis. Toxicol Sci 2012; 125: 595-606.
44. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-71.
45. Esen E, Chen J, Karner CM, Okunade AL, Patterson BW, Long F. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metab 2013; 17: 745-55.
46. Regan JN, Lim J, Shi Y, Joeng KS, Arbeit JM, Shohet RV, et al. Upregulation of glycolytic metabolism is required for HIF1a-driven bone formation. Proc Natl Acad Sci U S A 2014; 111: 8673-8.
47. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 2012; 15: 98-105.
48. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy? Drug Metab Dispos 2014; 42: 623-31.